Top U.S. Government Agency Validates Benefits of Croslite(TM) Material
July 17 2008 - 8:01AM
Business Wire
Today, CrocsRx�, the medical division of Crocs, Inc. (NASDAQ:
CROX), announced the Center for Medicare and Medicaid Services
(CMS) has accepted the Custom Cloud model into the diabetic shoe
program. Acceptance by the CMS validates the superior benefits of
Croslite� material, Crocs proprietary closed-cell resin, as the
Custom Cloud is the first molded shoe to receive an approved code
verification from the organization. Effective immediately, medical
professionals can fit the more than 23 million Americans suffering
from diabetes in the CrocsRx� Custom Cloud. The approved shoe comes
with three pairs of heat moldable orthotic insoles and is fitted by
a professional practitioner, to offer long-term relief for foot
ailments related to the disease. Recognized by the American
Podiatric Medical Association with its distinguished Seal of
Acceptance, the Custom Cloud offers diabetic patients several
advantages over traditional specialty footwear. Among the most
notable benefit is the customized fit that stems from the Croslite
Ag+� material. Croslite Ag+� material expands upon the comfort
attributes inherent to Croslite� material while adding
anti-bacterial, anti-fungal and odor resistant nano-Silver ceramic
crystals. Moreover, patients find the Custom Cloud to be easier to
slip on, easier to keep clean and that the shoe weighs less than
other specialty medical footwear styles accepted by CMS. The Custom
Cloud is available in three color combinations including Navy,
Black and Chocolate in men�s size 4-13.5 and women�s size 6-13.5,
with four width offerings. �We are thrilled with the Center for
Medicare and Medicaid�s decision to include CrocsRx� footwear in
the Medicare program,� stated Eddie Scott, Director of CrocsRx�.
�CMS acceptance is an enormous accomplishment as this governing
body completed an extensive review of clinical and historical
performance data and found Croslite� material to be a suitable
alternative to existing specialty leather footwear.� To learn more
about CrocsRx� footwear, or join the more than 4,000 doctors that
either recommend shoes from the CrocsRx� line to their patients or
distribute CrocsRx� models directly through their offices, visit
www.crocsrx.com. About Crocs, Inc: Crocs, Inc. is a rapidly growing
designer, manufacturer and retailer of footwear for men, women and
children under the Crocs� brand. All Crocs� brand shoes feature
Crocs� proprietary closed-cell resin, Croslite�, which represents a
substantial innovation in footwear. The Croslite� material enables
us to produce soft, comfortable, lightweight, superior-gripping,
non-marking and odor-resistant shoes. These unique elements make
Crocs� footwear ideal for casual wear, as well as for professional
and recreational uses such as boating, hiking, hospitality and
gardening. The versatile use of the material has enabled us to
successfully market our products to a broad range of consumers. The
first footwear brand to receive the prestigious APMA Executive
Director's award and Company of the Year award from the Student
Association of the APMA in a single year, CrocsRx� is a leader in
medical shoe sales with more than 3,000 doctors recommending or
distributing the brand to patients. CrocsRx� shoes are made from
Crocs� proprietary Croslite� material and are designed to alleviate
pain and discomfort from a variety of health-related ailments. For
more information, visit www.crocsrx.com. Crocs� shoes are sold in
more than 90 countries and come in a wide array of colors and
styles. Please visit www.crocs.com for additional information.
Crocs (NASDAQ:CROX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Crocs (NASDAQ:CROX)
Historical Stock Chart
From Jul 2023 to Jul 2024